A framework to evaluate the cost-effectiveness of the NADiA prosvue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer

Shelby D. Reed, Suzanne Merrill, Charles D. Scales, Judd W. Moul

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives The NADiA ProsVue is a prognostic system that measures prostate-specific antigen slope to identify men at lower risk of clinical recurrence of prostate cancer after radical prostatectomy. We developed a decision-modeling framework to evaluate its cost-effectiveness to guide the use of adjuvant radiotherapy (ART). Methods We populated the model using patient-level data and external sources. Patients were classified as intermediate risk or high risk on the basis of Cancer of the Prostate Risk Assessment-Postsurgical (CAPRA-S) nomogram and then stratified by the ProsVue slope (≤2 pg/mL/mo; >2 pg/mL/mo) and receipt of ART. In sensitivity analyses, we varied the effect of the ProsVue slope on the use of ART and other model parameters. Results The cost-effectiveness of the ProsVue-guided strategy varied widely because of small differences in quality-adjusted life-years (QALYs) at 10 years. In the intermediate-risk group, when the use of ART decreased from 20% (standard care) to 7.5% among patients with a ProsVue slope value of 2 pg/mL/mo or less, the incremental cost-effectiveness ratio was $25,160/QALY. In the high-risk group, the use of ART would have to decrease from 40% (standard care) to 11.5% among those with a ProsVue slope value of 2 pg/mL/mo or less to obtain a ratio of $50,000/QALY. The cost-effectiveness ratios were sensitive to varying benefits of salvage therapy, quality of life, and costs of ART and ProsVue testing. Conclusions The effect of the ProsVue system on costs will be dependent on the extent to which ART decreases among men identified as having a low risk of recurrence. Its effect on QALYs will remain conditional on uncertain clinical and quality-of-life benefits associated with ART. ;copy;2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Original languageEnglish (US)
Pages (from-to)545-554
Number of pages10
JournalValue in Health
Volume17
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Adjuvant Radiotherapy
Prostatectomy
Cost-Benefit Analysis
Prostatic Neoplasms
Quality-Adjusted Life Years
Quality of Life
Costs and Cost Analysis
Recurrence
Salvage Therapy
Nomograms
Decision Support Techniques
Information Storage and Retrieval
Prostate-Specific Antigen

All Science Journal Classification (ASJC) codes

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

@article{ea117da70bdd4f0d83aa29c418e0b03e,
title = "A framework to evaluate the cost-effectiveness of the NADiA prosvue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer",
abstract = "Objectives The NADiA ProsVue is a prognostic system that measures prostate-specific antigen slope to identify men at lower risk of clinical recurrence of prostate cancer after radical prostatectomy. We developed a decision-modeling framework to evaluate its cost-effectiveness to guide the use of adjuvant radiotherapy (ART). Methods We populated the model using patient-level data and external sources. Patients were classified as intermediate risk or high risk on the basis of Cancer of the Prostate Risk Assessment-Postsurgical (CAPRA-S) nomogram and then stratified by the ProsVue slope (≤2 pg/mL/mo; >2 pg/mL/mo) and receipt of ART. In sensitivity analyses, we varied the effect of the ProsVue slope on the use of ART and other model parameters. Results The cost-effectiveness of the ProsVue-guided strategy varied widely because of small differences in quality-adjusted life-years (QALYs) at 10 years. In the intermediate-risk group, when the use of ART decreased from 20{\%} (standard care) to 7.5{\%} among patients with a ProsVue slope value of 2 pg/mL/mo or less, the incremental cost-effectiveness ratio was $25,160/QALY. In the high-risk group, the use of ART would have to decrease from 40{\%} (standard care) to 11.5{\%} among those with a ProsVue slope value of 2 pg/mL/mo or less to obtain a ratio of $50,000/QALY. The cost-effectiveness ratios were sensitive to varying benefits of salvage therapy, quality of life, and costs of ART and ProsVue testing. Conclusions The effect of the ProsVue system on costs will be dependent on the extent to which ART decreases among men identified as having a low risk of recurrence. Its effect on QALYs will remain conditional on uncertain clinical and quality-of-life benefits associated with ART. ;copy;2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).",
author = "Reed, {Shelby D.} and Suzanne Merrill and Scales, {Charles D.} and Moul, {Judd W.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jval.2014.04.010",
language = "English (US)",
volume = "17",
pages = "545--554",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "5",

}

A framework to evaluate the cost-effectiveness of the NADiA prosvue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer. / Reed, Shelby D.; Merrill, Suzanne; Scales, Charles D.; Moul, Judd W.

In: Value in Health, Vol. 17, No. 5, 01.01.2014, p. 545-554.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A framework to evaluate the cost-effectiveness of the NADiA prosvue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer

AU - Reed, Shelby D.

AU - Merrill, Suzanne

AU - Scales, Charles D.

AU - Moul, Judd W.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objectives The NADiA ProsVue is a prognostic system that measures prostate-specific antigen slope to identify men at lower risk of clinical recurrence of prostate cancer after radical prostatectomy. We developed a decision-modeling framework to evaluate its cost-effectiveness to guide the use of adjuvant radiotherapy (ART). Methods We populated the model using patient-level data and external sources. Patients were classified as intermediate risk or high risk on the basis of Cancer of the Prostate Risk Assessment-Postsurgical (CAPRA-S) nomogram and then stratified by the ProsVue slope (≤2 pg/mL/mo; >2 pg/mL/mo) and receipt of ART. In sensitivity analyses, we varied the effect of the ProsVue slope on the use of ART and other model parameters. Results The cost-effectiveness of the ProsVue-guided strategy varied widely because of small differences in quality-adjusted life-years (QALYs) at 10 years. In the intermediate-risk group, when the use of ART decreased from 20% (standard care) to 7.5% among patients with a ProsVue slope value of 2 pg/mL/mo or less, the incremental cost-effectiveness ratio was $25,160/QALY. In the high-risk group, the use of ART would have to decrease from 40% (standard care) to 11.5% among those with a ProsVue slope value of 2 pg/mL/mo or less to obtain a ratio of $50,000/QALY. The cost-effectiveness ratios were sensitive to varying benefits of salvage therapy, quality of life, and costs of ART and ProsVue testing. Conclusions The effect of the ProsVue system on costs will be dependent on the extent to which ART decreases among men identified as having a low risk of recurrence. Its effect on QALYs will remain conditional on uncertain clinical and quality-of-life benefits associated with ART. ;copy;2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

AB - Objectives The NADiA ProsVue is a prognostic system that measures prostate-specific antigen slope to identify men at lower risk of clinical recurrence of prostate cancer after radical prostatectomy. We developed a decision-modeling framework to evaluate its cost-effectiveness to guide the use of adjuvant radiotherapy (ART). Methods We populated the model using patient-level data and external sources. Patients were classified as intermediate risk or high risk on the basis of Cancer of the Prostate Risk Assessment-Postsurgical (CAPRA-S) nomogram and then stratified by the ProsVue slope (≤2 pg/mL/mo; >2 pg/mL/mo) and receipt of ART. In sensitivity analyses, we varied the effect of the ProsVue slope on the use of ART and other model parameters. Results The cost-effectiveness of the ProsVue-guided strategy varied widely because of small differences in quality-adjusted life-years (QALYs) at 10 years. In the intermediate-risk group, when the use of ART decreased from 20% (standard care) to 7.5% among patients with a ProsVue slope value of 2 pg/mL/mo or less, the incremental cost-effectiveness ratio was $25,160/QALY. In the high-risk group, the use of ART would have to decrease from 40% (standard care) to 11.5% among those with a ProsVue slope value of 2 pg/mL/mo or less to obtain a ratio of $50,000/QALY. The cost-effectiveness ratios were sensitive to varying benefits of salvage therapy, quality of life, and costs of ART and ProsVue testing. Conclusions The effect of the ProsVue system on costs will be dependent on the extent to which ART decreases among men identified as having a low risk of recurrence. Its effect on QALYs will remain conditional on uncertain clinical and quality-of-life benefits associated with ART. ;copy;2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

UR - http://www.scopus.com/inward/record.url?scp=84906236984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906236984&partnerID=8YFLogxK

U2 - 10.1016/j.jval.2014.04.010

DO - 10.1016/j.jval.2014.04.010

M3 - Article

C2 - 25128047

AN - SCOPUS:84906236984

VL - 17

SP - 545

EP - 554

JO - Value in Health

JF - Value in Health

SN - 1098-3015

IS - 5

ER -